disease free survival

Summary

Summary: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.

Top Publications

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
  2. ncbi Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
  3. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
  4. ncbi Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Rodrigo Arriagada
    Instituto de Radiomedicina, Santiago, Chile
    N Engl J Med 350:351-60. 2004
  5. doi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
  6. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
  7. ncbi Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
    Jacques Bernier
    Department of Radio Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    N Engl J Med 350:1945-52. 2004
  8. doi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
  9. ncbi A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study
    Henry M Keys
    Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA
    Gynecol Oncol 92:744-51. 2004
  10. ncbi Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    Timothy Winton
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont
    N Engl J Med 352:2589-97. 2005

Detail Information

Publications326 found, 100 shown here

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
    ..Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate...
  2. ncbi Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
    ..We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer...
  3. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy...
  4. ncbi Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Rodrigo Arriagada
    Instituto de Radiomedicina, Santiago, Chile
    N Engl J Med 350:351-60. 2004
    ..On the basis of a previous meta-analysis, the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer...
  5. doi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
    ..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer...
  6. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  7. ncbi Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
    Jacques Bernier
    Department of Radio Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    N Engl J Med 350:1945-52. 2004
    ..We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head and neck cancer...
  8. doi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  9. ncbi A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study
    Henry M Keys
    Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA
    Gynecol Oncol 92:744-51. 2004
    ....
  10. ncbi Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    Timothy Winton
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ont
    N Engl J Med 352:2589-97. 2005
    ..We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer...
  11. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    ..Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted...
  12. ncbi Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    M K B Parmar
    Lancet 361:2099-106. 2003
    ..There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment...
  13. pmc Repeated observation of breast tumor subtypes in independent gene expression data sets
    Therese Sorlie
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 100:8418-23. 2003
    ..Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities...
  14. doi Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  15. ncbi Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  16. ncbi Capecitabine as adjuvant treatment for stage III colon cancer
    Chris Twelves
    University of Leeds and Bradford NHS Hospitals Trust, Leeds, United Kingdom
    N Engl J Med 352:2696-704. 2005
    ..The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus leucovorin as first-line treatment for metastatic colorectal cancer. We evaluated capecitabine in the adjuvant setting...
  17. ncbi A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer
    Umberto Veronesi
    Division of Senology, European Institute of Oncology, Milan, Italy
    N Engl J Med 349:546-53. 2003
    ..Although numerous studies have shown that the status of the sentinel node is an accurate predictor of the status of the axillary nodes in breast cancer, the efficacy and safety of sentinel-node biopsy require validation...
  18. ncbi 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology
    R C Bast
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 19:1865-78. 2001
    ..These guidelines are intended for use in the care of patients outside of clinical trials...
  19. ncbi A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    J Natl Cancer Inst 95:1320-9. 2003
    ..Therefore, we performed a randomized, phase III non-inferiority trial comparing paclitaxel plus cisplatin (PT) with paclitaxel plus carboplatin (TC) in patients with advanced ovarian cancer...
  20. ncbi Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
    N Engl J Med 353:1659-72. 2005
    ..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy...
  21. ncbi Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group
    Henning Mouridsen
    Rigshospitalet, Copenhagen, Denmark
    J Clin Oncol 21:2101-9. 2003
    ..To analyze overall survival (OS) and update efficacy data for letrozole versus tamoxifen as first-line therapy in postmenopausal women with locally advanced or metastatic breast cancer...
  22. ncbi Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study
    Ibou Thior
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Mass 02115, USA
    JAMA 296:794-805. 2006
    ..Postnatal transmission of human immunodeficiency virus-1 (HIV) via breastfeeding reverses gains achieved by perinatal antiretroviral interventions...
  23. pmc Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
    H J Andreyev
    Department of Medicine and Therapeutics, Imperial College School of Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    Br J Cancer 85:692-6. 2001
    ....
  24. ncbi Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Clin Oncol 16:2672-85. 1998
    ....
  25. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    ..We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients...
  26. ncbi Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902
    J A van der Hage
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 19:4224-37. 2001
    ....
  27. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    ..We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma...
  28. ncbi Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  29. ncbi Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  30. ncbi Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  31. ncbi Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer
    D M Aebersold
    Department of Radiation Oncology, University of Bern, Switzerland
    Cancer Res 61:2911-6. 2001
    ....
  32. ncbi Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients
    Nigel J P Beasley
    Oxford Centre for Head and Neck Oncology, Radcliffe Infirmary, Oxford OX2 6HE, United Kingdom
    Cancer Res 62:2493-7. 2002
    ..Expression of HIF-1alpha in surgically treated patients with HNSCC (n = 79) was associated with improved disease-free survival (P = 0.016) and overall survival (P = 0.027)...
  33. ncbi Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial
    Bryan H Burmeister
    University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
    Lancet Oncol 6:659-68. 2005
    ..We aimed to assess whether a short preoperative chemoradiotherapy regimen improves outcomes for patients with resectable oesophageal cancer...
  34. doi Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
    Federica Di Nicolantonio
    Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino, Medical School, Candiolo, Torino, Italy
    J Clin Oncol 26:5705-12. 2008
    ..Double-hit therapies aimed at simultaneous inhibition of epidermal growth factor receptor and BRAF warrant exploration in CRC patients carrying the V600E oncogenic mutation...
  35. ncbi Adjuvant docetaxel for node-positive breast cancer
    Miguel Martin
    Hospital Universitario San Carlos, Madrid, Spain
    N Engl J Med 352:2302-13. 2005
    ..We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer...
  36. ncbi Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis
    Sanjay Popat
    Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5NG, UK
    J Clin Oncol 22:529-36. 2004
    ..To derive a more precise estimate of the prognostic significance of TS expression, we have reviewed published studies and carried out a meta-analysis...
  37. ncbi Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
    ..A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients...
  38. ncbi Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
    N Wolmark
    N Wolmark, D L Wickerham, E R Fisher, B Fisher, National Surgical Adjuvant Breast and Bowel Project NSABP Operations Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 92:388-96. 2000
    ..This study was carried out to address this issue. An additional aim was to determine whether leucovorin (LV)-modulated 5-fluorouracil (5-FU) is superior to the combination of 5-FU, semustine, and vincristine (MOF) in men...
  39. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
    ....
  40. ncbi Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
    Volker Heinemann
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern, Munich, Germany
    J Clin Oncol 24:3946-52. 2006
    ..To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic pancreatic cancer...
  41. ncbi Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma
    Kårstein Måseide
    Ontario Cancer Institute Princess Margaret Hospital, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 10:4464-71. 2004
    ..The aim of this study was to quantify the extent of CA IX expression and to investigate whether CA IX is a marker for poor prognosis in soft tissue sarcoma patients at high risk of developing metastasis...
  42. doi Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials
    Fairooz F Kabbinavar
    Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, 2333D PVUB MC 705907, 10945 Le Conte Ave, Los Angeles, CA 90095 7059, USA
    J Clin Oncol 27:199-205. 2009
    ....
  43. ncbi Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, and Department of Surgery, University of Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 93:684-90. 2001
    ....
  44. ncbi Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery
    Jeffrey W Moses
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute of New York, New York 10021, USA
    N Engl J Med 349:1315-23. 2003
    ..Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization...
  45. ncbi Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma
    K Kian Ang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:7350-6. 2002
    ..The data suggest that EGFR IHC should be considered for selecting patients for more aggressive combined therapies or enrollment into trials targeting EGFR signaling pathways...
  46. ncbi Gene expression correlates of clinical prostate cancer behavior
    Dinesh Singh
    Department of Adult Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 1:203-9. 2002
    ..These results support the notion that the clinical behavior of prostate cancer is linked to underlying gene expression differences that are detectable at the time of diagnosis...
  47. ncbi Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer
    Takashi Tsuji
    Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852 8501, Japan
    Clin Cancer Res 9:3700-4. 2003
    ..91; P = 0.84). In conclusion, TSER genotype is not an efficacious marker for tumor sensitivity to 5-FU-based oral adjuvant chemotherapy for Japanese colorectal cancer patients after curative resection...
  48. pmc Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker
    Nikolas H Stoecklein
    Klinik für Allgemein und Viszeralchirurgie, Universitatsklinikum Dusseldorf, D 40225 Dusseldorf, Germany
    BMC Cancer 6:165. 2006
    ....
  49. doi PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
    F Perrone
    Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 20:84-90. 2009
    ....
  50. ncbi Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus
    Jan B F Hulscher
    Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    N Engl J Med 347:1662-9. 2002
    ..Controversy exists about the best surgical treatment for esophageal carcinoma...
  51. ncbi Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer--clinical associations and reasons for discrepancies
    Gunilla Chebil
    Department of Pathology, Helsingborg Hospital AB, Helsingborg, Sweden
    Acta Oncol 42:719-25. 2003
    ..For PgR, the associations with PFS were weaker, with significantly better PFS than the PgR(CYT)-/PgR(IHC)- group being found only for the PgR(CYT) +/PgR(IHC)- group (p = 0.03)...
  52. pmc Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma
    Masami Minagawa
    Department of Hepato Biliary Pancreatic Surgery, Graduate School of Medicine, University of Tokyo, Japan
    Ann Surg 238:703-10. 2003
    ..The purpose of this study was to evaluate prognostic factors in patients with recurrence after curative resection of hepatocellular carcinoma (HCC) and to identify selection criteria for repeat resection...
  53. ncbi Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele
    Johannes Bange
    Department of Molecular Biology, Max Planck Institute of Biochemistry, Am Klopferspitz 18a, D 82152 Martinsried, Germany
    Cancer Res 62:840-7. 2002
    ..Our results support the conclusion that the FGFR4 Arg(388) allele represents a determinant that is innocuous in healthy individuals but predisposes cancer patients for significantly accelerated disease progression...
  54. ncbi Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy
    Roderich E Schwarz
    Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA
    Ann Surg Oncol 9:394-400. 2002
    ..Radical gastrectomy with extended lymphadenectomy may reduce LRR, possibly affecting adjuvant treatment strategies...
  55. ncbi [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer
    Ryohei Sasaki
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:1136-43. 2005
    ..To determine whether the standardized uptake value (SUV) of [(18)F]fluorodeoxyglucose uptake by positron emission tomography could be a prognostic factor for non-small-cell lung cancer (NSCLC)...
  56. ncbi Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients
    V Chiarion Sileni
    Department of Medical Oncology, Padova Hospital, Azienda Ospedaliera, Italy
    Melanoma Res 11:189-96. 2001
    ..In conclusion, the overall response rate obtained with DBDT was greater than that obtained with DTIC alone; however, this combination increases toxicity with limited impact on overall survival...
  57. ncbi Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    Barry C Lembersky
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:2059-64. 2006
    ....
  58. ncbi KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Maria Debiec-Rychter
    Department of Human Genetics, University of Leuven and University Hospital Gasthuisberg, O and N Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Eur J Cancer 42:1093-103. 2006
    ..Our findings suggest the need for differential treatment of patients with GISTs, with KIT exon 9 mutant patients benefiting the most from the 800 mg daily dose of the drug...
  59. doi Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
    Bernard Escudier
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 27:4068-75. 2009
    ..Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen...
  60. pmc Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma
    A E Pinto
    , , , Centro de Lisboa, 1099-023 Lisboa Codex, Portugal
    J Clin Pathol 54:543-9. 2001
    ..methods were compared by means of kappa statistics, and the prognostic significance of both in relation to disease free survival (DFS) and overall survival (OS) was determined. RESULTS: SPF and Ki-67 analysis was performed on 234 (76...
  61. doi Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival
    Juan Jose Lahuerta
    Hospital Universitario de Salamanca, Salamanca, Spain
    J Clin Oncol 26:5775-82. 2008
    ..We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM...
  62. ncbi Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial
    J Baptist Trimbos
    Leiden University Medical Center, Leiden, The Netherlands
    J Natl Cancer Inst 95:113-25. 2003
    ..We performed a prospective unblinded, randomized phase III trial to test the efficacy of adjuvant chemotherapy in patients with early-stage ovarian cancer, with emphasis on the extent of surgical staging...
  63. ncbi Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study
    Sanjiv S Agarwala
    Division of Hematology Oncology, University of Pittsburgh Medical Center Pavilion, 5150 Centre Ave, Pittsburgh, PA 15232, USA
    J Clin Oncol 22:2101-7. 2004
    ..A multicenter, open-label, phase II study was conducted to assess the safety and efficacy of temozolomide in patients with brain metastases from metastatic melanoma (MM) who did not require immediate radiotherapy...
  64. ncbi Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
    J S Macdonald
    St Vincent's Comprehensive Cancer Center, New York, USA
    N Engl J Med 345:725-30. 2001
    ..CONCLUSIONS: Postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence of adenocarcinoma of the stomach or gastroesophageal junction who have undergone curative resection...
  65. ncbi Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results
    Claus Rodel
    Department of Radiation Oncology, Institute of Pathology, University of Erlangen, Germany
    J Clin Oncol 20:3061-71. 2002
    ..To evaluate our long-term experience with combined modality treatment and selective bladder preservation and to identify factors that may predict treatment response, risk of relapse, and survival...
  66. doi Prospective validation of a prognostic score to improve patient selection for oncology phase I trials
    Hendrik Tobias Arkenau
    Royal Marsden Hospital and Institute of Cancer Research, Drug Development Unit, Sutton, UK
    J Clin Oncol 27:2692-6. 2009
    ..This prospective study was performed to test the validity of the prognostic score...
  67. ncbi Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
    M Clarke
    Clinical Trial Service Unit, Oxford, UK
    Lancet 366:2087-106. 2005
    ..To examine this relationship, collaborative meta-analyses were undertaken, based on individual patient data, of the relevant randomised trials that began by 1995...
  68. doi Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
    E D Saad
    Dendrix Research, Hospital Sirio Libanes, Sao Paulo, Brazil
    Ann Oncol 21:7-12. 2010
    ..The other question is whether PFS sufficiently reflects clinical benefit to be considered a true end point in and of itself...
  69. ncbi Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma
    T J Park
    Department of Biochemistry and Molecular Biology, Ajou University School of Medicine, Suwon, Korea
    Cancer 92:2760-8. 2001
    ..01), tumor stage (P < 0.03) and 5-year disease free survival (P < 0.02)...
  70. pmc Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr
    Michael C Heinrich
    Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Clin Oncol 26:5360-7. 2008
    ..In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing...
  71. ncbi Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 20:4567-73. 2002
    ..Identifying pretreatment and posttreatment predictors of time to prostate cancer-specific death (PCSD) after external-beam radiation therapy (RT) was the subject of this study...
  72. doi Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
    Kenji Sugio
    Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1 1 Iseigaoka, Yahatanishi ku, Kitakyushu 807 8555, Japan
    Lung Cancer 64:314-8. 2009
    ..This study prospectively assessed the efficacy of gefitinib and the survival benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations...
  73. pmc Latent bone metastasis in breast cancer tied to Src-dependent survival signals
    Xiang H F Zhang
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 16:67-78. 2009
    ..Breast cancer cells that lodge in the bone marrow succumb in this environment when deprived of Src activity...
  74. ncbi Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients
    J P Stein
    Department of Urology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
    J Clin Oncol 19:666-75. 2001
    ....
  75. ncbi The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
    P G Johnston
    National Cancer Institute Navy Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20889
    J Clin Oncol 12:2640-7. 1994
    ....
  76. doi Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90
    Gesche Tallen
    Departments of Pediatric and Arend von Stackelberg Oncology Hematology and of General Pediatrics, Charit Universitätsmedizin Berlin, Germany
    J Clin Oncol 28:2339-47. 2010
    ....
  77. ncbi Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
    J Bonneterre
    Centre Oscar Lambret, Lille, France
    J Clin Oncol 18:3748-57. 2000
    ..To compare the efficacy and tolerability of anastrozole (Arimidex; AstraZeneca, Wilmington, DE, and Macclesfield, United Kingdom) with that of tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal women...
  78. ncbi Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution
    Stephanie E Combs
    Department of Radiation Oncology, University of Heidelberg, INF 400, 69120 Heidelberg, Germany
    J Clin Oncol 23:8863-9. 2005
    ..To evaluate the efficacy of fractionated stereotactic radiotherapy (FSRT) performed as reirradiation in 172 patients with recurrent low- and high-grade gliomas...
  79. ncbi Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
    I Vergote
    Department of Gynaecological Oncology, University Hospitals Leuven, Belgium
    Lancet 357:176-82. 2001
    ..We undertook a retrospective study in a large international database to identify the most important prognostic variables...
  80. ncbi International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma
    J Baptist Trimbos
    Department of Gynecology, Leiden University Medical Center, The Netherlands
    J Natl Cancer Inst 95:105-12. 2003
    ..Adjuvant chemotherapy has been suggested as a possible strategy to improve survival in women with early-stage ovarian cancer; however, all randomized studies to date have been too small to answer this question reliably...
  81. pmc Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial
    Mitch Dowsett
    Department of Academic Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Oncol 27:2962-9. 2009
    ....
  82. ncbi Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients
    Eriko Tokunaga
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Int J Cancer 118:284-9. 2006
    ..This finding suggests that inhibition of the Akt signaling pathway may increase the efficacy of hormone therapy and improve the prognosis of patients who receive adjuvant hormone therapy...
  83. ncbi Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
    M van Glabbeke
    EORTC Data Center, Av Mounier 83 11, B1200, Brussels, Belgium
    Eur J Cancer 38:543-9. 2002
    ....
  84. ncbi Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    N Engl J Med 354:809-20. 2006
    ..We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment...
  85. doi Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    Stephen Johnston
    Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 27:5538-46. 2009
    ....
  86. ncbi Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer
    P Birner
    The Institute of Clinical Pathology, University of Vienna Medical School, A 1090 Vienna, Austria
    Clin Cancer Res 7:1669-75. 2001
    ..Furthermore, results of the HercepTest were correlated with immunohistochemical results obtained using different antibodies and protocols and with HER-2 oncogene gene amplification assessed by fluorescence in situ hybridization (FISH)...
  87. ncbi Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role
    Hubert Vesselle
    Department of Radiology, University of Washington, Seattle, Washington, USA
    Clin Cancer Res 13:3255-63. 2007
    ....
  88. doi Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
    S George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Cancer 45:1959-68. 2009
    ....
  89. ncbi Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro
    H Bartelink
    Department of Radiotherapy, The Netherlands Cancer Institute Antoni van Leeuwenhoek Huis, Amsterdam, The Netherlands
    J Clin Oncol 15:2040-9. 1997
    ....
  90. ncbi Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity?
    Jonathan B Koea
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 10:432-40. 2003
    ..We attempted to define the effect of tumor histotype on local recurrence, distant metastasis, and disease-specific survival in patients with surgically treated primary extremity sarcoma...
  91. ncbi 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    Ian Smith
    Royal Marsden Hospital, London, UK
    Lancet 369:29-36. 2007
    ..We investigated the drug's effect on overall survival after a median follow-up of 2 years in the Herceptin Adjuvant (HERA) study...
  92. ncbi A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data
    M Bonetti
    Department of Biostatistics, Harvard School of Public Health and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Stat Med 19:2595-609. 2000
    ..We apply STEPP to a breast cancer clinical trial data set to evaluate the treatment effect as a function of the oestrogen receptor content of the primary tumour...
  93. ncbi Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications
    P Vaupel
    Institute of Physiology and Pathophysiology, University of Mainz, Duesbergweg 6, D 55099 Mainz, Germany
    Wien Med Wochenschr 152:334-42. 2002
    ..Anaemia in cancer patients should be prevented/corrected in order to improve radio-/chemosensitivity and thus to increase cancer cure rates...
  94. pmc MIB-1 labelling index is an independent prognostic marker in primary breast cancer
    R L Jansen
    Department of Internal Medicine, University Hospital Maastricht, The Netherlands
    Br J Cancer 78:460-5. 1998
    ..08). Thus, in conclusion, the growth fraction of a tumour as determined by the MIB-1 labelling index is an important prognostic factor in patients with primary breast cancer...
  95. ncbi Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer
    M Morris
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    N Engl J Med 340:1137-43. 1999
    ..Patients were then to receive one or two applications of low-dose-rate intracavitary radiation, with a third cycle of chemotherapy planned for the second intracavitary procedure in the combined-therapy group...
  96. ncbi Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
    Wolfgang J Kostler
    Department of Medicine I, University Hospital of Vienna, Austria
    Clin Cancer Res 10:1618-24. 2004
    ....
  97. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008
    ..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma...
  98. doi Survival end point reporting in randomized cancer clinical trials: a review of major journals
    Simone Mathoulin-Pelissier
    Clinical Research Department, Institut Bergonie, Regional Comprehensive Cancer Center, Bordeaux, France
    J Clin Oncol 26:3721-6. 2008
    ..Several publications showed that the standards for reporting randomized clinical trials (RCTs) might not be entirely suitable. Our aim was to evaluate the reporting of survival end points in cancer RCTs...
  99. pmc Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
    Teri N Kreisl
    Neuro Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 8200, USA
    J Clin Oncol 27:740-5. 2009
    ..To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma...
  100. doi Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias
    Walter Stummer
    Neurochirurgische Klinik, Heinrich Heine Universitat, Dusseldorf, Germany
    Neurosurgery 62:564-76; discussion 564-76. 2008
    ....
  101. ncbi Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases
    Ryosuke Tateishi
    Department of Gastroenterology, University of Tokyo, Tokyo, Japan
    Cancer 103:1201-9. 2005
    ..Previously reported treatment efficacy and complication rates have varied considerably...

Research Grants70

  1. Pharmacogenetics: Breast Cancer Treatment and Prognosis
    Christine Ambrosone; Fiscal Year: 2005
    ..Individualized dosing according to genotype could contribute to increased efficacy and decreased toxicity among patients being treated for cancer. ..
  2. T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia
    Laurence J N Cooper; Fiscal Year: 2013
    ..LAY SUMMARY: We will infuse CD19-specific T cells after transplantation to improve survival for patients with acute lymphoblastic leukemia. ..
  3. Breast Carcinoma in situ: Predicting Risk and Outcomes
    Amy Trentham-Dietz; Fiscal Year: 2013
    ..The long-term goal of this project is to reduce the public health impact of BCIS by quantifying both contextual and personal risk factors for the development of BCIS and the recurrence of breast cancer after a BCIS diagnosis. ..
  4. Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients
    Dawn Hershman; Fiscal Year: 2013
    Third generation aromatase inhibitors have been shown to be superior to tamoxifen in improving disease free survival, decreasing distant and local recurrence rates and decreasing incidence of contra-lateral breast cancer in women with ..
  5. Heat shock protein 90 antagonist-based therapy of mantle cell lymphoma
    Kapil Bhalla; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): New treatment strategies are needed to improve the disease free survival in human mantle cell lymphoma (MCL)...
  6. PROGESTIN AND GROWTH FACTOR CROSS-TALK IN BREAST CANCER
    CAROL ANN LANGE; Fiscal Year: 2010
    ..This work will aid our understanding of steroid hormone action, and help to identify and implicate new therapeutic targets for breast cancer prevention and treatment. ..
  7. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy &Chemoprevention
    Ruth Lupu; Fiscal Year: 2013
    ..breast carcinomas express high levels of FASN and FASN expression is a marker for poor prognosis and poor disease free survival. Interestingly, FASN is highly coexpressed with the three breast cancer histopathological groups: Estrogen ..
  8. Novel Compounds to Inactivate Oncogenic Fusion Proteins
    Jeffrey A Toretsky; Fiscal Year: 2013
    ..This project will specifically address the need for new targeted therapies for ESFT and a large number of related malignancies that have chromosomal translocations. ..
  9. Impact of exercise on ovarian cancer prognosis
    Melinda L Irwin; Fiscal Year: 2013
    ..abstract_text> ..
  10. Defining Novel Biomarkers for Cervical Cancer Etiology and Progression by Quantit
    Erin Siegel; Fiscal Year: 2010
    ..patients, we will determine those gene(s) whose aberrant methylation has the highest predictive value for disease free survival. With this strong foundation, we will be placed in a competitive position for R01 funding focused on ..
  11. In Vivo Imaging of bcl-2 Expression in Lymphoma
    Michael R Lewis; Fiscal Year: 2012
    ..5% of its victims are U.S. war veterans. The goal of the proposed research is central to the VHA mission of providing primary and specialized care to cancer patients who are veterans. ..
  12. Radioimmunotherapy for Multiple Myeloma
    Damian J Green; Fiscal Year: 2013
    ..stem cell transplantation (ASCT) leads to increased rates of complete remission and prolonged periods of disease free survival, but relapse remains inevitable...
  13. Inflammation in the pathogenesis of lung cancer
    Steven M Dubinett; Fiscal Year: 2013
    ..Each year lung cancer exacts a devastating toll in terms of lives lost and resources expended. It is expected that this VA supported research will ultimately lead to improvement in disease-free survival for veterans with lung cancer. ..
  14. Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect
    Wolfgang W Scholz; Fiscal Year: 2012
    ..The primary endpoint for this pivotal multicenter randomized trial is improvement in progression-free survival at one year. ..
  15. Epigenetic Regulation of Breast Cancer Progression by the Proto-oncogene PELP1
    MONICA MANN; Fiscal Year: 2013
    ..Understanding the mechanism by which PELP1 modulates epigenetic changes and the reversible nature of these modifications provides a unique therapeutic opportunity to design novel drugs for treating hormonal cancers. ..
  16. Evaluation of NBD Peptides as an Adjunct Therapy for the Treatment of Non-Hodgkin
    PATRICK MICHAEL FLOOD; Fiscal Year: 2010
    ..IKK complex in vivo by NBD peptide can safely inhibit aberrant, constitutive NF-?B activity and prolong disease free survival in privately owned dogs with spontaneous, relapsed NHL...
  17. Targeted Radiotherapy with 90Y-BC8 Monclonal Antibody, Fludarabine and TBI Follow
    William I Bensinger; Fiscal Year: 2012
    ..Myeloablative allo SCT for MM is associated with a 15-30% probability of disease free survival extending beyond 10 years, the best evidence for cure...
  18. SOUTHWEST ONCOLOGY GROUP
    Gary E Goodman; Fiscal Year: 2013
    ..PSOC members are active in administrative and scientific activities and are dedicated to support the goals of the Southwest Oncology Group. ..
  19. Vaccination with IL-15 DC to Generate Melanoma-specific Protective Memory T Cells
    Anna Karolina Palucka; Fiscal Year: 2013
    ..Current therapies have the potential to improve outcome in a fraction of patients but are associated with considerable toxicity. Vaccination with melanoma antigen-loaded dendritic cells (DCs) could improve outcomes without toxicity. ..
  20. Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
    Helen E Heslop; Fiscal Year: 2013
    ..abstract_text> ..
  21. Prognostic and predictive gene sets in HER2-positive breast cancer:The HERA Trial
    Brian Leyland Jones; Fiscal Year: 2010
    ....
  22. Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
    Aaron P Rapoport; Fiscal Year: 2013
    ..they have the potential to synergize with current therapies to promote remissions and achieve long term disease free survival. We have conducted several trials of adoptive transfer T cell therapy for multiple myeloma, testing the ..
  23. Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemi
    Marie Bleakley; Fiscal Year: 2013
    ..3. To develop a library of novel minor H antigens that are expressed selectively on hematopoietic cells including acute leukemia and presented in association with prevalent HLA alleles. ..
  24. Hormones and Tumor Initiating Cells in Human Breast Cancers
    CAROL ANN SARTORIUS; Fiscal Year: 2013
    ..Patients with luminal tumors have significantly higher disease free survival overall compared to those with basal tumors...
  25. Hematopoietic Cell Transplantation for Hematologic Malignancies
    Stephen J Forman; Fiscal Year: 2010
    ....
  26. Fibrosis-Protease Cross-Talk Regulating Pancreatic Cancer Invasion
    Hidayatullah G Munshi; Fiscal Year: 2013
    ..abstract_text> ..
  27. Fhit as modulator of Chk1 termination and response to DNA-damaging agents
    JOSHUA SALDIVAR; Fiscal Year: 2012
    ..This project will define the mechanism through which Fhit modulates the 'checkpoint', thus contributing to the understanding of aberrant 'checkpoints in cancer cells. ..
  28. Maintenance therapy with decitabine for acute myeloid leukemia in first remission
    William G Blum; Fiscal Year: 2010
    ..The specific aims of the study are the following: 1) To determine 1 year disease free survival (DFS), feasibility, and toxicities of one year of maintenance decitabine given to patients <60 years ..
  29. Predictors of clinical outcome after therapeutic vaccination in follicular lympho
    Sattva S Neelapu; Fiscal Year: 2013
    ..The proposed studies are likely to have substantial impact on the development of the cancer vaccine field in general and lymphoma vaccines in particular. ..
  30. DNA Methylation and Ovarian Cancer
    Kenneth P Nephew; Fiscal Year: 2012
    ....
  31. Childhood Leukemia: Oxidative Stress, Cognitive Changes &Academic Outcomes
    IDA MARIE MOORE; Fiscal Year: 2013
    ..abstract_text> ..
  32. The AHR as a Novel Pathway to the Induction of Regulatory T cells
    Nancy I Kerkvliet; Fiscal Year: 2013
    ....
  33. MicroRNA marker-based prognosis of oral cancer survival
    ANGELA JIYEON YOON; Fiscal Year: 2013
    ..to develop and validate a microRNA (miR) marker-based prognostic modality for oral cancer survival (5-year disease free survival versus death within 5-years)...
  34. TARGETING AML-STROMAL INTERACTIONS
    John F DiPersio; Fiscal Year: 2013
    ..We hypothesize that pharmacologic interruption of the tethers that bind AML blasts to the bone marrow will sensitize these cells to chemotherapy and improve remission rates and long term disease free survival.
  35. Clinical and Financial Impact of Treatment for Oral and Pharyngeal Cancer
    CHRISTOPHER S contact HOLLENBEAK; Fiscal Year: 2010
    ..It will also inform and guide physicians as they consider treatment recommendations for individual patients and also policy makers as they develop and refine treatment guidelines for Medicare patients. ..
  36. MR Dynamic Imaging and Spectroscopy in Head & Neck Cancers
    AMITA DAVE; Fiscal Year: 2010
    ..If successful, it will provide an a priori predictor of failure/response to chemotherapy and/or long term disease free-survival, resulting in patient specific treatment which will likely enhance outcome. ..
  37. Vitamin D3 Effects on Musculoskeletal Symptoms with Use of Aromatase Inhibitors
    Alice C Shapiro; Fiscal Year: 2012
    ....
  38. Neuregulin1 Alleviation of the "On-Target" Cardiotoxicity Caused by Inhibition of
    Xinhua Yan; Fiscal Year: 2013
    ....
  39. ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer
    Robert C Bast; Fiscal Year: 2012
    ..We also will determine whether expression of ARHI is associated with prolonged disease free survival, while expression of Rab25 will be associated with decreased progression free survival in ovarian cancer...
  40. Glycoprotein Signatures as Biomarkers for Breast Cancer
    ROBERT YEN; Fiscal Year: 2012
    ..Thus, the proposed research is relevant to the part of NIH's mission that pertains to developing fundamental knowledge that will help to reduce the burdens of human illness and lengthen life. ..
  41. Quantitative DW-MRI for Early Breast Cancer Treatment Response Assessment
    Anne F Schott; Fiscal Year: 2013
    ..Development of an early quantitative imaging biomarker based on DW-MRI data would provide for individualized patient care. ..
  42. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
    Estuardo Aguilar-Cordova; Fiscal Year: 2013
    ..A secondary objective is to prospectively evaluate surrogate end-points for early stage prostate cancer. ..
  43. Radiation response within the tumor microenvironment
    Stephen J Kron; Fiscal Year: 2013
    ..We hope to project these events over time onto tumor size and metabolism on a gross level. ..
  44. Feasibility of a weight loss intervention among female cancer survivors in SWOG
    Heather Greenlee; Fiscal Year: 2013
    ..This study aligns with the mission of the NCI and the Office of Cancer Survivorship, which is to enhance the quality and length of survival of breast and colorectal cancer survivors. ..
  45. Molecular and Genetic Analysis of Lung Cancer Survival
    David C Christiani; Fiscal Year: 2013
    ..This will be the largest and most complete genetic analysis of NSCLC to date, and will move the field significantly towards to goal of more effective, personalized therapy for NSCLC patients. ..
  46. Role of EphA2 RTK in tumor resistance to EGFR/HER2 inhibitors
    Jin Chen; Fiscal Year: 2013
    ..Success of this project will provide a strong rationale for rapid clinical development of anti-EphA2 therapeutics for treatment of EGFR/HER2 resistant tumors, which will greatly benefit the Veteran population. ..
  47. Hypoxia in neuroblastoma
    Guoliang Qing; Fiscal Year: 2010
    ..Despite the array of chemotherapeutic agents presently available, the overall long-term disease free survival rate of neuroblastoma patients remains low...
  48. Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
    Sattva S Neelapu; Fiscal Year: 2010
    ....
  49. Evaluation of HSET as a Novel Theranostic Target for Breast Cancer Therapy
    Ritu Aneja; Fiscal Year: 2013
    ..abstract_text> ..
  50. A Decision Making Framework for Contralateral Prophylactic Mastectomy
    Patricia A Parker; Fiscal Year: 2011
    ....
  51. RRM1 in the Management of Lung Cancer
    Gerold Bepler; Fiscal Year: 2013
    ....
  52. Uveal Melanoma Micrometastasis
    Pierre L Triozzi; Fiscal Year: 2010
    ..Micrometastases, microscopic deposits of tumor that have spread via the bloodstream, are present in many patients with uveal melanoma at diagnosis. This project will test new methods of identifying and inhibiting these deposits. ..
  53. Host-tumor cell interaction in myeloma: therapeutic applications
    Kenneth C Anderson; Fiscal Year: 2013
    ..anti-MM host immune responses in order to develop novel targeted therapeutics which achieve long-term disease free survival and potential cure of MM...
  54. The Therapy of CML
    Richard E Champlin; Fiscal Year: 2013
    ..the projects into human clinical trials designed to increase the rate of molecular complete remission and disease free survival in CML...
  55. Dual drug high dose PLGA-lipid hybrid nanoparticles for drug delivery
    Sergio Sandoval; Fiscal Year: 2011
    ..the combination of anthracyclines and taxanes in the adjuvant setting has been shown to improve disease free survival in patients with positive lymph nodes...
  56. ER-Negative, Basal Cells Persist in Luminal Cancers: Are They Cancer Stem Cells?
    James M Haughian; Fiscal Year: 2011
    ..cancers have a good prognosis, whereas ER- basal breast cancers are highly aggressive, and have poor disease free survival. We recently discovered that ER+ breast tumors contain a subpopulation of progestin (P)-regulated, ER-, ..
  57. Cancer Recurrence: Detection in Administrative Data, Incidence, and Costs
    Debra P Ritzwoller; Fiscal Year: 2013
    ..In our applied studies, we will begin to capitalize on this opportunity by measuring the impact of this condition on the public health and the consumption of societal resources. ..
  58. Physical activity to reduce joint pain during aromatase inhibitor therapy
    LEIGH FLEMING CALLAHAN; Fiscal Year: 2013
    ..All aspects of our study will be informed by Patient Advisors who are part of our Study Team as well as by oncologists who are actively engaged in the design, implementation and analysis of our study. ..
  59. Sentinel Node Versus Axillary Dissection in Breast Cancer
    David N Krag; Fiscal Year: 2012
    ....
  60. Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment
    Dave S B Hoon; Fiscal Year: 2013
    ..The study addresses an important treatment problem of primary rectal cancer using a novel combination of epigenomic predictive biomarkers. ..
  61. Targeting BCL6 in tyrosine kinase-driven leukemia
    MARKUS MUSCHEN; Fiscal Year: 2013
    ....
  62. Do Medicare Claims Measure Cancer Relapse Patients: An External Validation Study
    Elizabeth B Lamont; Fiscal Year: 2012
    ..Developing an accurate DFS algorithm is a predicate to extending our existing work that examines the risks and benefits of cancer chemotherapy in usual care elderly patients, which touches, to some extent, on all area noted above. ..
  63. Targeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer Margins
    Lily Yang; Fiscal Year: 2012
    ....
  64. Listeria Immunotherapy for Pancreatic and Ovarian Cancer
    Thomas Dubensky; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  65. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  66. Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
    Richard Carvajal; Fiscal Year: 2009
    ..The establishment of new metastases would no longer be possible, so aggressive local therapies including surgery and radiation therapy might result in long-term control or potential cure of even metastatic sarcoma. ..
  67. CD19-Specific T-Cell Therapy for Follicular Lymphoma
    LAURENCE COOPER; Fiscal Year: 2004
    ....
  68. STRENGTH--Survivor TRaining for ENhancinG Total Health
    Wendy Demark Wahnefried; Fiscal Year: 2002
    ..If data show promise, further and larger study will be pursued - study which will be focused on testing an optimal intervention and powered on known effect sizes. ..
  69. Blood vs. bone marrow stem transplant
    Benjamin Djulbegovic; Fiscal Year: 2003
    ..BM transplant, substantial controversy about a possible advantage of PBSCT over BMT on mortality and disease free survival exists...
  70. PHASE III TRIAL--LAPAROSCOPIC COLECTOMY FOR COLON CANCER
    Heidi Nelson; Fiscal Year: 2000
    ....